Search
Santen Launches Ryjunea® in Germany to Combat Childhood Myopia Progression
4 week ago /
Read about 0 minute
Author：小编
Santen Pharmaceutical Co., Ltd. has proudly announced the official launch of Ryjunea® (R&D code: STN1012701) in Germany on July 23, 2023. This innovative product, designed to slow down the progression of myopia in children, received approval from the European Commission on June 2. Germany is the pioneering market for Ryjunea®, with plans to introduce it in other European countries in the near future. Ryjunea® is specifically indicated for use in children aged 3 to 14 who experience an annual myopia progression of 0.5 diopters (D) or more, with a spherical equivalent refraction ranging from -0.5D to -6.0D.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
